# AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

> **NCT04096326** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 198 (actual)

## Conditions studied

- Glabellar Lines

## Interventions

- **DRUG:** AGN-151586
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04096326
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-26
- **Primary completion:** 2020-09-09
- **Final completion:** 2020-09-09
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04096326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04096326, "AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04096326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*